Determination of optimal neuromuscular reversal dose of Sugammadex in pediatric patients

Determination of optimal neuromuscular reversal dose of Sugammadex in pediatric patients - Determination of optimal neuromuscular reversal dose of Sugammadex in pediatric patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000007276

Enrollment

Registered

2012-03-01

Start date

2012-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Surgical pediatric patients undergoing general anesthesia

Interventions

sufficient group insufficient group

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: surgical pediatric patients undergoing general anesthesia

Exclusion criteria

Exclusion criteria: 1.patients with liver and renal dysfunction 2.patients with neuromuscular disease

Design outcomes

Primary

Measure	Time frame
It is possible to determine the necessity of additional Sugammadex for the complete reversal of neuromuscular block in a short post-operative period.	—

Countries

Japan

Contacts

Public ContactHajime Iwasaki

Asahikawa Medical University Department of Anesthesiology and critical care medicine

iwasakih@asahikawa-med.ac.jp0166682583

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026